• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

    6/23/25 10:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

    Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

    The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.

    A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on July 22, 2025 until midnight Eastern Time on August 5, 2025.

    Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

    About Quest Diagnostics

    Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-release-second-quarter-2025-financial-results-on-july-22-2025-302488358.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    More analyst ratings

    $DGX
    SEC Filings

    View All

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    10/21/25 6:50:12 AM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Quest Diagnostics Incorporated

    10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    10/21/25 6:31:10 AM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/26/25 4:12:08 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

    SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast

    1/8/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium

    SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics. Details of the poster presentations are as follows: Title: Reproducibility an

    1/6/26 10:01:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Davis J. E. exercised 55,093 shares at a strike of $95.80 and sold $10,589,760 worth of shares (55,093 units at $192.22) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    11/28/25 4:30:50 PM ET
    $DGX
    Medical Specialities
    Health Care

    Director Gregg Vicky B sold $239,700 worth of shares (1,250 units at $191.76), decreasing direct ownership by 7% to 17,037 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    11/28/25 4:30:31 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP & Chief Commercial Officer Delaney Mark E exercised 7,946 shares at a strike of $144.46 and sold $1,488,683 worth of shares (7,946 units at $187.35) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    11/20/25 4:28:10 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Citigroup with a new price target

    Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

    3/4/25 7:20:57 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026

    SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast

    1/8/26 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Nov. 11, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record of Quest Diagnostics common stock on January 13, 2026. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to t

    11/11/25 4:22:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

    Third quarter revenues of $2.82 billion, up 13.1% from 2024Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.58 and $8.66; and adjusted diluted EPS is expected to be between $9.76 and $9.84SECAUCUS, N.J., Oct. 21, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.

    10/21/25 6:45:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

    SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

    3/3/23 4:30:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care